Roivant Sciences Ltd (ROIV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $28.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Roivant Sciences Ltd (ROIV) Competitors
The companies most similar to Roivant Sciences are Royalty Pharma Plc (RPRX), Revolution Medicines (RVMD) and BridgeBio Pharma (BBIO). By market cap, Roivant Sciences ranks 6th of the 13 companies on this page; argenx NV ADR (ARGX) is the largest at $60.37B. The median P/E of the 7 companies with a P/E is 19.3x.
Peer Comparison
ROIV's revenue growth of 2136.0% is above the peer median of 24.9%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Roivant Sciences (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| Jazz Pharmaceuticals PLC (JAZZ) | $15.50B | 18.4x | 3.3x | 4.4% | 3.5% | 10.4% | 0.00% |
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| Halozyme Therapeutics Inc (HALO) | $11.43B | 17.8x | 6.1x | 26.9% | 15.8% | 39.2% | 0.00% |
| Peer median | $22.32B | 19.3x | 13.5x | 15.4% | 4.2% | 24.9% | 0.00% |
Similar Companies
These are the 12 companies most similar to Roivant Sciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| Jazz Pharmaceuticals PLC (JAZZ) | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United... | JAZZ competitors |
| Genmab AS (GMAB) | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. | GMAB competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| Halozyme Therapeutics Inc (HALO) | Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. | HALO competitors |
Frequently Asked Questions About ROIV
Who are Roivant Sciences' main competitors?
The companies most similar to Roivant Sciences include Royalty Pharma Plc (RPRX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Insmed (INSM) and Exelixis (EXEL), listed from the closest match.
Who is Roivant Sciences' biggest competitor?
argenx NV ADR (ARGX) is the largest of the similar companies at $60.37B; Royalty Pharma Plc (RPRX) is the closest match by business profile, size, sector and industry.
How does ROIV stock compare with its competitors?
ROIV's P/S is 679.3x against a peer median of 13.5x; its net margin is 0.0% against a peer median of 15.4%.
Which of Roivant Sciences' competitors pays a higher dividend?
Roivant Sciences pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Roivant Sciences bigger than its competitors?
No. Roivant Sciences is 6th by market cap among the 13 companies on this page; the largest is argenx NV ADR (ARGX) at $60.37B.
ROIV pages: Overview, Earnings, Forecast, Financials, Competitors